Case Report: Multidrug Resistant Raoultella ornithinolytica in a Septicemic Calf

Mathilde L. Pas1*, Kevin Vanneste2, Jade Bokma1, Laura Van Driessche1, Sigrid C. J. De Keersmaecker2, Nancy H. Roosens2, Freddy Haesebrouck3, Filip Boyen3† and Bart Pardon1†

1 Department of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium, 2 Sciensano, Transversal Activities in Applied Genomics, Brussels, Belgium, 3 Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium

Sepsis is a frequent life-threatening condition in young calves, requiring rapid broad spectrum and bactericidal therapy to maximize survival chances. Few studies have identified and characterized bacteria involved in sepsis in calves. This report demonstrates the involvement of a multidrug resistant Raoultella ornithinolytica, an emerging pathogen in human medicine, in a calf with suspected sepsis. R. ornithinolytica was identified by MALDI-TOF MS from blood cultures of a critically ill calf. Susceptibility testing showed phenotypic resistance against ampicillin, gentamicin, potentiated sulphonamides, streptomycin, tetracyclines and intermediate susceptibility for enrofloxacin. Whole genome sequencing confirmed identification as R. ornithinolytica and the multidrug resistant character of the isolate. Antimicrobial resistance genes acting against aminoglycosides, beta-lactam antibiotics, fosfomycin, quinolones, sulphonamides, trimethoprim and tetracyclines were found. The calf recovered after empirical parenteral therapy with enrofloxacin and sodium penicillin for seven days. Ancillary therapy consisted of fluid therapy, ketoprofen and doxapram hydrochloride. To the authors’ knowledge, this is the first report characterizing a multidrug resistant R. ornithinolytica isolate from blood culture in cattle. It is currently unknown whether animals and farms may act as reservoirs for multidrug resistant R. ornithinolytica strains.

Keywords: antimicrobial resistance, Enterobacteriaceae, case report, cattle, sepsis, whole genome sequencing

INTRODUCTION

Sepsis is a high mortality risk disease for which rapid appropriate antibiotic treatment is critical to increase survival rates, both in cattle and in humans (1, 2). A multitude of bacteria have been described as causative agents, but in cattle mainly Enterobacteriaceae, more specifically Escherichia coli, are typically isolated from ill calves (3). Here, a multidrug resistant Raoultella ornithinolytica, another member of the Enterobacteriaceae family, isolated from a calf with neonatal septicemia, is described.

Multidrug resistant R. ornithinolytica strains have been reported in septicemia cases in humans, but not in cattle (4). Raoultella ornithinolytica is an encapsulated Gram-negative bacterium, until 2001 classified within the Klebsiella genus, reflecting that identification of this species using only conventional biochemical methods can be challenging (5). The genus Raoultella contains four
species, of which *R. ornithinolytica* is described as the most virulent species in humans (6). Aside from its ubiquitous presence in aquatic environments (4, 6, 7), *R. ornithinolytica* is an opportunistic pathogen mainly involved in hospital-acquired infections, often after invasive procedures and in immunocompromised patients (4, 5, 7). This species has been linked with bacteremia, biliary tract and urinary tract infections, as well as pancreatitis and wound infections in humans (4, 6–8). To the best of our knowledge, septicemia caused by *R. ornithinolytica*, has not been described in other mammals. Though the veterinary importance of this bacterium seemed limited in the past, it has been isolated in feces of fish, ticks, termites, birds, pigs and turtles, as well as a case of pneumonia from the latter species (9–13). In cattle, *Raoultella* species have been isolated from rumen and manure samples (14). *Raoultella ornithinolytica* was also associated with mastitis and isolated from the viscera of a neonatal calf on autopsy with signs suggestive for septicemia (15, 16). In this study, *R. ornithinolytica* was isolated from a blood culture of a calf with suspected sepsis. Additionally, the genome sequence of this bacterium and antimicrobial resistance were determined.

**CASE DESCRIPTION**

A 2-day-old male Belgian blue calf (45 kg) was presented in December 2018 in a critically ill state. The calf had experienced breathing difficulties since the first day after birth. The calf had been treated by the local practitioner with furosemide, amoxicillin, dexamethasone, alpha tocopherol acetate and anhydrous sodium selenite, presumably all intramuscularly as indicated by the manufacturer, except for the furosemide, which was likely given intravenously. At presentation, the calf was in lateral decubitus and depressed. Fever (40.8°C: ref. 38.5–39.5) was present, with an increased respiratory rate (72/min: ref. 20–50), but heart rate (108/min: ref. 90–110) was normal (17). Ultrasonography was performed with a linear 7.5 MHz probe (Easote MyLab™30 Gold unit, the Netherlands) and revealed diffuse comet tail artifacts (B-lines) on the pleura and multiple small consolidations (max. 1 cm depth) on both sides of the thorax. No abnormalities were found on ultrasonographic examination of the abdomen. Blood samples were collected from the jugular vein upon arrival and placed in heparin-coated tubes prior to blood-gas analysis with RAPIDPoint® 405 (Siemens Healthcare, Beersel, Belgium). Venous blood gas analysis showed a mild metabolic acidosis (pH 7.23). The morning after presentation, an arterial sample out of the external carotid artery displayed hypoxemia [arterial pO2 = 32.6 mmHg (ref. 80–100)] and hypercapnia [arterial pCO2 = 74.7 mmHg (ref. 40–50)]. Failure of passive transfer of immunoglobulins was excluded with a glutaraldehyde test according to Turgut et al. (18).

**DIAGNOSTIC ASSESSMENT**

**Bacteriology**

Blood samples were aseptically sampled in one single volume collected from the jugular vein upon arrival, whereby 3 and 10 ml were aseptically inoculated into BD BACTEC™ Peds Plus™ and BD BACTEC™ Plus Aerobic medium, respectively (BD, Erembodegem, Belgium), which were subsequently incubated at 35°C in an automated system for the detection of microbial growth (BACTEC™ FX). For identification, a loopful of medium was first plated on a Columbia agar supplemented with 5% sheep blood (blood agar; Oxoid, Hampshire, UK) and incubated for 24 h at 37°C in a 5% CO2 enriched atmosphere, after which a single colony was transferred on a polished steel plate, air dried and covered with 1 μL alpha-cyano-4-hydroxycinnamic acid matrix (Bruker Daltonics, Bremen, Germany). The sample was identified with an Autoflex III smartbeam MALDI-TOF MS, using FlexControl and MBT Compass software (Bruker Daltonics, Bremen, Germany). Log score values higher than 2.00, between 1.70 and 1.99, and between 0 and 1.69, indicate high-confidence, low-confidence, and no-confidence identification, respectively. From both BD BACTEC™ media (Becton Dickinson—Benelux, Erembodegem, Belgium), a pure culture was obtained. The isolate was identified with MALDI-TOF MS, and the best hit was obtained for *R. ornithinolytica* MB_18887 CHB with a (log)score value of 2.32. The seven best hits matched with *R. ornithinolytica*, with (log)score values ≥2.16.

Antimicrobial susceptibility testing (AST) for different antibiotics (Table 1) was executed with the disk diffusion test using a Mueller Hinton agar and aerobic incubation at 35°C for 20 h after which the inhibition zones were interpreted. The diameter of the inhibition zone was measured and interpreted according to the breakpoints prescribed by the Clinical and Laboratory Standards Institute (CLSI) (19). CLSI breakpoints specifically for *R. ornithinolytica* were not available, so CLSI values were used for Enterobacterales, since *R. ornithinolytica* belongs to the *Enterobacteriaceae* family. For ceftiofur, cattle-specific disk diffusion CLSI breakpoints were available. For the other antibiotics, CLSI breakpoints extrapolated from human breakpoints were used, rather than extrapolation from other organisms. In the absence of CLSI values for Enterobacterales for certain antibiotics (or certain potencies), breakpoints provided by the manufacturer were used (20) (Table A1 in Appendix). *Escherichia coli* strains ATCC® 25922™ and ATCC® 35218™ were used as quality control strains. Multidrug resistance was defined as resistance to agents from at least three different antimicrobial classes (21). The isolate showed multidrug resistance with the disk diffusion test, with resistance against ampicillin, tetracycline and doxycycline, gentamicin, potentiated sulfonamides and streptomycin and intermediate susceptibility for enrofloxacin (Table 1 and Table A1 in Appendix).

**Treatment**

The patient was suspected to have neonatal respiratory distress syndrome (NRDS) combined with sepsis. Based on the clinical presentation of the animal, therapy initialization could not be postponed until microbial information was present. The calf was empirically treated with enrofloxacin (Floxadil® 5 mg/kg, Emdoka, Hoogstraten, Belgium), sodium benzylpenicillin (penicillin 1.500.000 IU q.i.d., Kela, Sint-Niklaas, Belgium) and oxygen (1.5 L/min.) for seven days, ketoprofen
(Ketofen® 3 mg/kg, Ceva, Libourne, France) during the first 2 days and doxapram hydrochloride (Dopram® 1.5 mg/kg, Eumedica, Brussel, Belgium) on day one. Perusions were given intravenously through a catheter, starting with bicarbonate 2% (20 gram bicarbonate in 1 liter of isotonic NaCl 0.9%; rate 100 mL/kg/h), followed by Ringer’s lactate solution at a rate of 20 mL/kg/h. The calf received perusions until it drank sufficiently on day 6. After ultrasonography and clinically improvement, the calf could leave the clinic.

**FOLLOW-UP DIAGNOSTICS**

**Whole Genome Sequencing**

For research purposes, the isolated was further characterized by whole genome sequencing (WGS). Genomic DNA was prepared using the Isolate II Genomic DNA kit (Bioline, Meridian Bioscience, Paris, France), following the manufacturer’s instructions. Sequencing libraries were constructed using the Illumina Nextera XT DNA sample preparation kit and instructions. Whole genome sequencing (WGS) was performed using an in-house workflow based on WGS data, three different approaches were used: k-mer based identification of read data using Kraken against the entire NCBI RefSeq Microbial Genomes database, 16S rRNA gene analysis using the NCBI suite of tools, and read mapping using Bowtie2 against the NCBI RefSeq reference genome entry for *R. ornithinolytica* (NCBI accession NC_021066.1) (22, 23). For genotypic antimicrobial resistance (AMR) gene detection, WGS data were searched using an in-house workflow based on assembly with SPAdes and BLASTing against the ResFinder database containing a curated catalog of AMR genes (24–27).

Mlplasmids 1.0.0 (https://sarredondo.shinyapps.io/mlplasmids) was used to determine whether the predicted contig origin was plasmid- or chromosome-derived. *Klebsiella pneumoniae* was used as species model. Additionally, a direct read mapping approach was performed using SRST2 against the ResFinder database. One of the detected isolate AMR genes, blaPLA, is a genetic marker that allows differentiation of *Raoultella* spp., and was further investigated using the NCBI suite of tools (7, 28). A more extended description of bioinformatics methods for WGS data analysis including tools, versions, and parameters, is available in the Supplementary Material.

---

**TABLE 1 | Antibiotic susceptibility and antimicrobial resistance genes of *Raoultella ornithinolytica* obtained from a calf with sepsis.**

| Antimicrobial | Antimicrobial susceptibility (disk diffusion) | Locus† | % Identity | % Query coverage | Contig (length) | Predicted contig origin‡ |
|---------------|---------------------------------------------|--------|------------|-----------------|----------------|-------------------------|
| Ampicillin    | Resistant                                   | blaORN³ | 99.89 (1 SNP) | 100             | Node 34 (60566) | Chromosome (0.947)      |
| Amoxicillin—clavulanic acid | Susceptible | blaTEM-1B | 100 | 100 | Node 87 (17794) | Plasmid (0.983) |
| Apramycin     | Susceptible                                  | /      | /          | /               | /              | /                       |
| Ceftriaxone   | Susceptible                                  | /      | /          | /               | /              | /                       |
| Cefquinome    | Susceptible                                  | /      | /          | /               | /              | /                       |
| Doxycycline   | Resistant                                    | tet(D) | 100        | 100             | Node 128 (3634) | Plasmid (0.954)         |
| Tetracycline  | Resistant                                    | tet(D) | 100        | 100             | Node 128 (3634) | Plasmid (0.954)         |
| Enrofloxacin  | Intermediate                                 | qnrS1  | 100        | 100             | Node 103 (10631) | Plasmid (0.967)         |
| Florfenicol   | Susceptible                                  | /      | /          | /               | /              | /                       |
| Flumequine    | Susceptible                                  | qnrS1  | 100        | 100             | Node 103 (10631) | Plasmid (0.967)         |
| Gentamicin    | Resistant                                    | aac(3)-Ila | 100 | 100 | Node 87 (17794) | Plasmid (0.983)         |
| Streptomycin  | Resistant                                    | aph(3')-IIb | 99.88 (1 SNP) | 100 | Node 103 (10631) | Plasmid (0.967) |
| Spectinomycin | Susceptible                                  | /      | /          | /               | /              | /                       |
| Sufa-trimethoprim | Resistant | sul2 | 100        | 100             | Node 103 (10631) | Plasmid (0.967)         |
| Fosfomycin    | Not tested                                   | ftsA   | 99.52 (2 SNPs) | 100 | Node 41 (50833) | Chromosome (0.994)      |

†Detected by both making an assembly with SPAdes and BLASTing, and direct read mapping with SRST2, against the ResFinder database containing a curated catalog of AMR genes.

‡Detected using mlplasmids. Between brackets the range of posterior probability is given. *Klebsiella pneumoniae* was used as species model, given its close genetic relationship with *Raoultella* sp.

³Gene is present as blaPLA (NCBI accession NG_049969.1) in the ResFinder database derived from *R. planticola*, but inspection demonstrated the isolate gene to correspond to blaORN (NCBI accession NG_049386.1—for which % identity and % query coverage values are presented) derived from *R. ornithinolytica* (see Supplementary Material).
Identification of the isolate as *R. ornithinolytica* was supported by WGS data through three different analyses. Firstly, k-mer based identification of WGS data against the NCBI RefSeq Microbial Genomes database classified 87.52% of reads as *R. ornithinolytica*, whereas no other species were detected using a 5% threshold (see Supplementary Figure 1). Secondly, 16S rRNA analysis using the NCBI RefSeq 16S database confirmed the presence of a 16S rRNA *R. ornithinolytica* gene with high sequence identity (>99%). Lastly, read mapping against the NCBI RefSeq Genome entry for *R. ornithinolytica* confirmed its presence with a depth and breadth of coverage of 30.52× and 94.52%, respectively (see Supplementary Figure 2). Genotypic AMR gene detection using the ResFinder database, both through an assembly- and read mapping-based approach, indicated the presence of several AMR genes consistently with both methods and various of the detected genes were predicted to be present on a plasmid (see Table 1). Isolate AMR genes that contained mutations compared to the ResFinder reference sequences were manually investigated. The isolate’s fosA gene contained two synonymous mutations, and the isolate’s aph(3′)-Ib contained one mutation resulting in a K10E amino acid change, preserving the open reading frame of both isolate genes. The isolate’s blaPLA gene, encoding a class A broad-spectrum beta-lactamase originally characterized from *R. planticola*, exhibited however 49 mutations. Because this gene acts as a species marker for *Raoultella* spp., the sequence of the isolate’s AMR gene was further investigated, finding only one synonymous mutation compared to the blaORN gene from *R. ornithinolytica*, confirming the functional presence of blaORN and isolate identification as *R. ornithinolytica* (see Supplementary Figures 3, 4) (7). A more extended description of results for the WGS data analysis is available in the Supplementary Material.

**DISCUSSION**

To the authors’ knowledge, this is the first report of a multidrug resistant *R. ornithinolytica*, isolated from a calf suffering from sepsis. Previously, *Klebsiella ornithinolytica* was retrieved from the viscera of a calf with suspected sepsis, but this sampling cannot be regarded evidence of involvement of these bacteria in sepsis (16). In addition, very recently, *R. ornithinolytica* has been identified in a presumed *Klebsiella* collection, associated with clinical mastitis in cattle (15). Indeed, based on biochemical characteristics, *Raoultella* was formerly incorrectly classified as *Klebsiella* (7, 29). Although conventional biochemical methods were not used in our case study, identification was confirmed both by MALDI-TOF MS and WGS. The increasing availability of MALDI-TOF MS in hospitals and diagnostic laboratories will likely result in a better and more frequent recognition of *R. ornithinolytica* in the years to come (6). On the other hand, this bacterium is likely underdiagnosed in septicemic animals, because blood culture enrichment is rarely used in veterinary practice and particularly not in food-producing animals, even though blood culture is the most appropriate sampling technique for presumed sepsis cases (1).

The calf most likely acquired the infection on the farm, since blood cultures were taken immediately upon arrival at the clinic. It cannot be excluded whether the intravenous treatment of the local veterinarian possibly caused the bacteremia as multiple venipuncture increases a higher risk of contamination (30). However, the authors deem this the be unlikely, since the calf was critically ill before ambulatory treatment. It is impossible to identify the portal of entry in this case. This animal also suffered from pneumonia, but whether the pneumonia was primary and sepsis the consequence, or whether the pneumonia resulted from septic spread is unclear. The ultrasonographic finding, with multiple consolidations and marked B-lines point more toward an interstitial or metastatic pneumonia than a classic bronchopneumonia.

The empirical antimicrobial choice was based on the most likely bacteria in bovine sepsis, namely *E. coli* and its local resistance profile, which is often multidrug resistant among others against tetracyclines and trimethoprim-sulfonamides (31). To maximize survival chances, as in human medicine, a de-escalation therapy, starting broad spectrum and narrowing the spectrum after microbial test results become available was anticipated (2). Sepsis in calves can also be of Gram positive origin, including anaerobes and *T. pyogenes* (32, 33). The choice fell on the combination of fluoroquinolones with sodium penicillin, because of the broad spectrum, rapid IV administration and bactericidal activity. In Belgium, the use of the critically important fluoroquinolones in food animals is legally regulated and taking an appropriate sample (in this case a blood culture) is mandatory (KB July 21st, 2016). Aminoglycosides could have been an alternative choice, but were not selected due to the risk for renal injury in especially in critically ill and dehydrated neonatal patients (34).

Despite the *R. ornithinolytica* isolate being phenotypically categorized as intermediately susceptible to enrofloxacin with disk diffusion, clinical response on enrofloxacin treatment combined with penicillin was good. The intermediate disk diffusion result is likely linked to the presence of the plasmid-mediated quinolone resistance (PMQR) gene qnrS1, which can indeed lead to low-level acquired resistance (Table 1) (35). Despite the clinical effectiveness of the treatment in this case, acquired resistance toward fluoroquinolones may result in treatment failure. Additionally, fluoroquinolones are critically important antibiotics for humans and should be used with caution and can be subject to local legislation. Nevertheless, veterinarians should be aware of the risk of multidrug resistance in *R. ornithinolytica* isolates, similar to the high resistance levels described in human medicine, where broad-spectrum antibiotic treatment is suggested before microbial test results are available (4).

AMR gene detection based on WGS data demonstrated the presence of several other AMR genes in the current isolate. *Raoultella* spp. are known to be intrinsically resistant against aminopenicillins due to the expression of a chromosomally encoded class A β-lactamase (36), which can explain its ineffectiveness when given by the ambulatory veterinarian. More specifically, for *R. ornithinolytica*, blaORN has been described as a species marker and was also detected in our isolate (36).
addition, a blaTEM-1 β-lactamase gene predicted to be located on a plasmid was detected in the current isolate (Table 1), as described before (36). The presence of blaORN and blaTEM-1 are in agreement with the phenotypic resistance observed against aminopenicillins. The current isolate was phenotypically resistant against gentamicin and streptomycin. This is in accordance with the presence of aac(3)-II and aph(3′)-I encoding aminoglycosides modifying enzymes associated with resistance to gentamicin and streptomycin, respectively (Table 1) (37). Also for tetracyclines and potentiated sulphonamides, phenotypic resistance was supported by the presence of relevant resistance genes (Table 1).

For sepsis, broad-spectrum bactericidal drugs are recommended in human medicine (2, 38). Due to restrictions on the use of critically important antimicrobials, these crucial products for sepsis treatment are only conditionally available for (food) animals in some countries. Nevertheless, existence of multidrug resistant R. ornithinolytica might be a further motivation for veterinarians to apply diagnostics by blood culture to better target and rationalize antimicrobial therapy.

**CONCLUSION**

This report raises the question whether R. ornithinolytica is currently underdiagnosed in veterinary medicine due to limited diagnostics, and whether it may be emerging in cattle similarly as recently documented for humans. Multidrug resistant R. ornithinolytica can apparently cause sepsis in calves similar to humans. Spread of such multidrug resistant pathogens would further hamper treatment options for sepsis. Clarification on its current prevalence, the potential existence of reservoirs in animals or farming environments, and the relationship with human isolates is warranted.

**DATA AVAILABILITY STATEMENT**

The datasets generated in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/, PRJNA607902.

**ETHICS STATEMENT**

Ethical review and approval was not required for the animal study because it was a case description of research conducted for diagnostic purposes with the aim of a initializing a proper treatment for the patient. Written informed consent was obtained from the owners for the participation of their animals in this study.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

**FUNDING**

The MALDI-TOF MS was financed by the Research Foundation Flanders (FWO-Vlaanderen) as Hercules project (G0H2516N, AUGE/15/05). This work was additionally supported by the project NGS and Bioinformatics Platform funded by Sciensano (Sciensano RP/PJ-Belgium) (0001252).

**ACKNOWLEDGMENTS**

We thank the technicians of the service Transversal activities in Applied Genomics at Sciensano for performing the WGS.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fvets.2021.631716/full#supplementary-material

**REFERENCES**

1. Pardon B, Deprez P. Rational antimicrobial therapy for sepsis in cattle in face of the new legislation on critically important antimicrobials. Vlaams Diergeneeskundig Tijdschrift. (2018) 87:37–46. doi: 10.21825/vdt.v87i1.16094
2. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. (2017) 43:304–77. doi: 10.1007/s00134-017-4683-6
3. Fecteau G, Van Metre DC, Pare J, Smith BP, Higgins R, Holmberg CA, et al. Bacteriological culture of blood from critically ill neonatal calves. Can Vet J. (1997) 38:95–100.
4. Seng P, Boushab RM, Romain F, Gouriet F, Bruder N, Martin C, et al. Emerging role of Raoultella ornithinolytica in human infections: a series of cases and review of the literature. Int J Infect Dis. (2016) 45:65–71. doi: 10.1016/j.ijid.2016.02.014
5. Beye M, Hasni I, Seng P, Michelle C, La Scola B, Raoul D, et al. Genomic analysis of a Raoultella ornithinolytica strain causing prosthetic joint infection in an immunocompetent patient. Sci Rep. (2018) 8:9462. doi: 10.1038/s41598-018-27833-2
6. de Alegria Puig CR, Torres ME, Marfil-Perez E, Fernandez MIR, Del Rio MC, Balbin JA, et al. Comparison between Vitek MS, Bruker Biotyper, Vitek2, and API20E for differentiation of species of the genus Raoultella. Eur J Clin Microbiol Infect Dis. (2019) 38:467–70. doi: 10.1007/s10096-018-03444-4
7. Ponce-Alonso M, Rodriguez-Rojas L, Del Campo R, Canton R, Morosini MI. Comparison of different methods for identification of species of the genus Raoultella: report of 11 cases of Raoultella causing bacteraemia and literature review. Clin Microbiol Infect. (2016) 22:252–7. doi: 10.1016/j.cmi.2015.10.035
8. Wang X, Wang Y, Zhou Y, Wang Z, Wang Y, Zhang S, et al. Emergence of Colistin Resistance Gene mcr-8 and Its Variant in Raoultella ornithinolytica. Front Microbiol. (2019) 10:228. doi: 10.3389/fmicb.2019.00228
9. Guenther S, Filter M, Tedin K, Szabo I, Tedin K, Nockler K, et al. Emergence of Colistin Resistance Gene mcr-8 and Its Variant in Raoultella ornithinolytica. Front Microbiol. (2019) 10:228. doi: 10.3389/fmicb.2019.00228
10. Marietto-Gonçalves G, Lima E, Nagayoshi B, Tonin A, Knöbl T, Adreatti Filho R. Raoultella ornithinolytica isolation in cloacal microbiota of tinamus solitarius: preliminary data. Braz J Poult Sci. (2018) 20:189–92. doi: 10.1590/1806-9061-2017-0599
11. McCudden ZP, Carlson SA, Rasmussen MA, Franklin SK. Klebsiella to Salmonella gene transfer within rumen protozoa: implications for
antibiotic resistance and rumen defaunation. *Vet Microbiol.* (2006) 114:275–84. doi: 10.1016/j.vetmic.2005.12.004

12. Morais VP, Daporta MT, Bao AF, Campello MG, Andres GQ. Enteric fever-like syndrome caused by *Raoultella ornithinolytica* (*Klebsiella ornithinolytica*). *J Clin Microbiol.* (2009) 47:868–9. doi: 10.1128/JCM.01709-08

13. Uricaru A, Kobolkti LB, Czirjak GA, Cadar D, Ungvari A. Raoultella ornithinolytica induced sever pneumonia in red eared slider (trachemys scripta elegans). *Bulletin of University of Agricultural Sciences and Veterinary Medicine CLUJ-NAPOCA. Animal Science and Biotechnologies Bulletin USAMV Veterinary Medicine.* (2008) 65:374. doi: 10.15835/buasvmcn-vm:65-2:1501

14. Zadoks RN, Griffiths HM, Munoz MA, Ashlstrom C, Bennett GJ, Thomas E, et al. Sources of Klebsiella and Raoultella species on dairy farms: be careful where you walk. *J Dairy Sci.* (2011) 94:1045–51. doi: 10.3168/jds.2010-3603

15. Masse J, Dufour S, Archambault M. Characterization of Klebsiella isolates obtained from clinical mastitis cases in dairy cattle. *J Dairy Sci.* (2020) 103:3392–400. doi: 10.3168/jds.2019-17324

16. Anonymous. Severe subcutaneous oedema in sheep flocks before lambing. *Vet Rec.* (2006) 158:581–4. doi: 10.1136/vr.158.17.581

17. Rosenberger G. *Die klinische Untersuchung des Rindes* (20th Auflage). Berlin: Verlag Paul Parey (1977).

18. Turgut K, Basoglu A, Sevinc M, Sen I, Yildiz M, Kaleli S. Plasma transfusion in calves with failure of passive colostral transfer. *Turk J Vet Anim Sci.* (1998) 22:123–30.

19. CLSI Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals. 5th ed. CLSI supplement VET01S. Clinical and Laboratory Standards Institute (2020).

20. Rosco Diagnostica. Neo-Sensitabs User’s Guide. Rosco Diagnostica A/S, Denmark (2005).

21. Sweeney MT, Lubbers BV, Schwarz S, Watts JL. Applying definitions for multidrug resistance, extensive drug resistance and pandrug resistance to clinically significant livestock and companion animal bacterial pathogens-authors’ response. *J Antimicrob Chemother.* (2019) 74:536–7. doi: 10.1093/jac/dky470

22. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* (2009) 10:R25. doi: 10.1186/gb-2009-10-3-25

23. Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. *Genome Biol.* (2014) 15:R46. doi: 10.1186/gb-2014-15-3-46

24. Bankieva A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol.* (2012) 19:455–77. doi: 10.1089/cmb.2012.0021

25. Bogaerts B, Winand R, Fu Q, Van Braekel J, Ceyssens P-J, Mathieu W, et al. Validation of a bioinformatics workflow for routine analysis of whole-genome sequencing data and related challenges for pathogen typing in an European national reference center: *Neisseria meningitidis* as a proof-of-concept. *Front Microbiol.* (2019) 10:e00362. doi: 10.3389/fmicb.2019.00362

26. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al. BLAST+: architecture and applications. *BMC Bioinformatics.* (2009) 10:421. doi: 10.1186/1471-2105-10-421

27. Zankari E, Hasman H, Cosentino M, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother.* (2012) 67:2640–4. doi: 10.1093/jac/dks261

28. Inouye M, Dashnow H, Raven L-A, Schultz MB, Pope BJ, Tomita T, et al. SRST2: rapid genomic surveillance for public health and hospital microbiology labs. *Genome Med.* (2014) 6:90. doi: 10.1186/s13073-014-0090-6

29. Walckenaer E, Leflon-Guibout V, Nicolas-Chanoine MH. How to identify Raoultella spp. including *R. ornithinolytica* isolates negative for ornithine decarboxylase? The reliability of the chromosomal bla gene. *J Microbiol Methods.* (2008) 75:405–10. doi: 10.1016/j.mimet.2008.0.1011

30. Lamy B, Dargere S, Arendrup MC, Parienti JJ, Tattevin P. How to optimize the use of blood cultures for the diagnosis of bloodstream infections? A state-of-the-art. *Front Microbiol.* (2016) 7:697. doi: 10.3389/fmicb.2016.00697

31. AMCA, FAVV, AFMSPFAGG. Activities and Achievements—Antibiotic Use and Resistance in Animals in Belgium. (2018). Available online at: http://www.afsca.be/professionelen/publicaties/thematisch/reportconveniantAB/documents/Publiekrapport19_06_2019_versie7_NL.pdf (accessed February 23, 2021).

32. Fecteau G, Smith BP, George LW. Septicemia and meningitis in the newborn calf. *Vet Clin N Am Food Anim Pract.* (2009) 25:195–208. doi: 10.1016/j.cvfa.2008.10.004

33. Lofsledt J, Doohoo IR, Duizer G. Model to predict septicemia in diarrheic calves. *J Vet Intern Medicine.* (1999) 13:81–8. doi: 10.1892/0891-6600(1999)013<0081:mtpsid>2.3.co;2

34. McWilliam SL, Antoine DJ, Smyth RL, Pirmohamed M. Aminoglicoside-induced nephrotoxicity in children. *Pediatr Nephrol.* (2017) 32:2015–25. doi: 10.1007/s00467-016-3533-3

35. Le TMV, AbouM N, Morrison V, Thomson N, James IC, Woodward MJ, et al. Differential phenotypic and genotypic characteristics of qnrS1-harboring plasmids carried by hospital and community commensal enterobacteria. *Antimicrob Agents Chemother.* (2011) 55:1798–802. doi: 10.1128/aac.00200-10

36. Walckenaer E, Poirel L, Leflon-Guibout V, Nordmann P, Nicolas-Chanoine MH. Genetic and biochemical characterization of the chromosomal class A beta-lactamases of *Raoultella* (formerly *Klebsiella*) plasmidicola and *Raoultella ornithinolytica*. *Antimicrob Agents Chemother.* (2004) 48:305–12. doi: 10.1128/aac.48.1.305-312.2004

37. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. *Drug Resist Updat.* (2010) 13:151–71. doi: 10.1016/j.drup.2010.08.003

38. Liang SY, Kumar A. Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance. *Curr Infect Dis Rep.* (2015) 17:493. doi: 10.1007/s11908-015-0493-6

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Pas, Vanneste, Bokma, Van Driessche, De Keersmaeker, Roosens, Haesebrouck, Royen and Pardon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
APPENDIX

**TABLE A1** | Disk diffusion susceptibility for *Raoultella ornithinolytica* per antimicrobial agent, including information about potency disks, diameter control strains (*E. coli* ATCC 25922 and *E. coli* ATCC 35218) and associated quality control values, zone diameter *R. ornithinolytica* and values for interpreting a susceptibility category.

| Antimicrobial agent          | Potency (µg) | Performance standards disk diffusion | CS *E. coli* ATCC 25922 zone diameter (mm) and QC ranges | CS *E. coli* ATCC 35218 zone diameter (mm) and QC ranges | Interpretive categories | Category susceptibility *R. ornithinolytica* |
|------------------------------|--------------|--------------------------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------|---------------------------------------------|
| Ampicillin                   | 10           | CLSI<sup>a</sup>                      | 20 (15–22)                                               | NA                                                       | 8                       | ≥ 17 ≥ 18 14–16 ≤ 13                         | Resistant                    |
| Amoxicillin—clavulanic acid | 30 (A 20 C 10) | CLSI<sup>a</sup>                      | 20 (18–24)                                               | 22 (17–22)                                               | 18                      | ≥ 17 ≥ 18 14–17 ≤ 13                         | Susceptible                  |
| Enrofloxacin                 | 10           | Manufacturer<sup>c</sup>              | 32 (31–37)                                               | NA                                                       | 20                      | ≥ 23 ≥ 20 19–17 ≤ 16                         | Intermediate                 |
| Flumequine                   | 30           | Manufacturer<sup>c</sup>              | 32 (28–36)                                               | NA                                                       | 20                      | ≥ 20 ≥ 20 19–17 ≤ 16                         | Susceptible                  |
| Florfenicol                  | 30           | Manufacturer<sup>d</sup>              | 27 (22–28)                                               | NA                                                       | 24                      | ≥ 20 ≥ 20 19–17 ≤ 16                         | Susceptible                  |
| Doxycycline                  | 30           | CLSI<sup>a</sup>                      | 22 (18–24)                                               | NA                                                       | 8                       | ≥ 14 ≥ 15 12–14 ≤ 11                         | Resistant                    |
| Tetracycline                 | 30           | CLSI<sup>a</sup>                      | 22 (18–25)                                               | NA                                                       | 8                       | ≥ 15 ≥ 15 12–14 ≤ 11                         | Resistant                    |
| Spectinomycin                | 200          | Manufacturer<sup>e</sup>              | 26 (24–32)                                               | NA                                                       | 24                      | ≥ 20 ≥ 23 19–15 ≤ 16                         | Susceptible                  |
| Apramycin                    | 40           | Manufacturer<sup>c</sup>              | 23 (21–28)                                               | NA                                                       | 26                      | ≥ 23 ≥ 22–20 ≤ 19                           | Susceptible                  |
| Streptomycin                 | 10           | CLSI<sup>a</sup>                      | 16 (12–20)                                               | NA                                                       | 8                       | ≥ 15 ≥ 15 12–14 ≤ 11                         | Resistant                    |
| Gentamicin                   | 10           | CLSI<sup>a</sup>                      | 20 (19–26)                                               | NA                                                       | 8                       | ≥ 15 ≥ 15 13–14 ≤ 12                         | Resistant                    |
| Cefquinome                   | 30           | Manufacturer<sup>c</sup>              | 32 (28–36)                                               | NA                                                       | 32                      | ≥ 23 ≥ 23 22–20 ≤ 19                         | Susceptible                  |
| Ceftiofur                    | 30           | CLSI<sup>b</sup>                      | 26 (26–31)                                               | NA                                                       | 26                      | ≥ 21 ≥ 21 18–20 ≤ 17                         | Susceptible                  |
| Trimethoprim—sulfamethoxazole | 25 (T 1.25 S 23.75) | CLSI<sup>a</sup>                      | 27 (23–29)                                               | NA                                                       | 8                       | ≥ 16 ≥ 16 11–15 ≤ 10                         | Resistant                    |

NA, Not available; CS, Control strain; QC, Quality control; ATCC, American Type Culture Collection; S, Susceptible; I, Intermediate; R, Resistant. CLSI: Clinical and Laboratory Standards Institute (19).<sup>a</sup>Breakpoints specifically for Enterobacterales: Human.<sup>b</sup>Breakpoints specifically for Enterobacteriales: Cattle. Manufacturer: Rosco Diagnostica (20).<sup>c</sup>Breakpoints for slow growing organisms and other general bacteria species: Veterinary.<sup>d</sup>Breakpoints for slow growing organisms and other general bacteria species: Cattle.<sup>e</sup>Breakpoints for slow growing organisms and other general bacteria species: Human.